

Vaccine specialist develops bluetongue virus-3 vaccine within months

- Verovaccines develops the first recombinant subunit vaccine against the current bluetongue virus -3 (BTV-3) outbreak in Europe that impacts sheep and cattle
- Using a new vaccine construction technology, first vaccines were generated within weeks. 70% of the dossier was completed within 7 months (generation, safety & efficacy)
- The company uses its new capabilities for fast emergency responses and cost-efficient classical vaccine development in animal health

Halle (Saale), Germany, October, 08, 2024 – The German vaccine specialist Verovaccines has demonstrated how it is possible to go from a simple BTV-3 virus sequence to a validated vaccine in just a few months. An authorisation dossier has also been compiled, which is now around 90% complete. The company expects to obtain emergency authorisation before the end of this year and thus bring an innovative BTV-3 vaccine to the market to combat the disease. Unlike traditional virus-based vaccines, this new class of vaccines is derived from synthetic ingredients, so it is virus-free, and its DIVA¹ capability supports effective outbreak control strategies.

The new development capabilities open up the possibility of rapidly developing further vaccines against other BTV serotypes. The concept of rapid response to emerging outbreaks does not appear to be limited to BTV, as the platform has been shown to be applicable to a variety of different pathogens. The BTV-3 program extended the platform by providing additional methods, processes, formulations and documentation. Due to the comprehensive nature of the platform, these elements can be used interchangeably between different vaccine programs. This results in cost- and time-efficient development, even for valuable classic development programs with long-term sales prospects.

Dr Hanjo Hennemann, CEO: 'The rapid development of this BTV-3 vaccine clearly demonstrates the power of our comprehensive technology platform. We also intend to leverage the Company's new development capabilities together with partners in joint developments and to attract investors.' Prof. Dr Sven-Erik Behrens (CSO): 'This success would not have been possible without our great team of 12-people and the fruitful collaboration with the Friedrich-Loeffler-Institute, which operates the national BTV reference laboratory in Germany.'

###

¹ DIVA (Differentiation of Infected from Vaccinated Animals) allows the separation of pathogen spread and vaccination countermeasures through diagnostics. The use of non-DIVA vaccines based on whole virus makes such diagnostic approaches "blind", limiting outbreak strategies and animal trade.

About VEROVACCiNES GmbH

Verovaccines is a biopharmaceutical company with full development capabilities. It was spun off from Martin Luther University Halle-Wittenberg in 2017, and has since expanded and validated its vaccine technology- and manufacturing platforms. In addition to its experienced founders, the company has a team of scientists with expertise in virology, molecular biology, veterinary medicine, project management, regulatory affairs, and quality management. Verovaccines has a pipeline of five proprietary vaccine programs. The company welcomes co-operations for vaccine development.

About the Unified Vaccine- and the Unified Manufacturing-Platforms

Verovaccines' vaccines are based on a proprietary and patented technology platform using the lactic yeast *Kluyveromyces lactis*. The Unified Vaccine Platform can be used against a broad range of pathogens, allows for easy combination of vaccines, significantly shortens development time compared to classical vaccines, and has been de-risked through multiple *proof-of-concept* studies in target animals. The Unified Manufacturing Platform offers same-for-all functionality with short production cycle times and exceptionally low costs. Verovaccines is currently using its technology to develop a product pipeline of subunit marker vaccines against swine and bovine pathogens.

Contact us:

VEROVACCiNES GmbH
Mareike Schünemann
Blücherstrasse 26
06120 Halle (Saale), Germany
E-mail: info@verovaccines.com
Web: www.verovaccines.com